Skip to main content
. 2021 Sep 1;8(2):36–45. doi: 10.36469/001c.26129

Table 1. PICOS Criteria for the (a) Epidemiology SLR and (b) BOI SLR.

a. Epidemiology SLR
Category Inclusion Criteria Exclusion Criteria
Patient Population
  • Adult patients (age ≥18) with IgAN regardless of comorbidities*

  • Non-human

  • Pediatric patients (age <18) only

  • Patients with other diseases

Intervention
  • Any treatment or management

  • No treatment or management

  • Any non-IgAN treatment or management

Outcomes Measures
  • Incidence, prevalence, rate of IgAN

  • Progression rate of IgAN through CKD stage and to ESRD

  • Patient distribution across CKD stage

  • Treatment rate

  • Mortality

  • Studies that did not have ≥1 outcome in the inclusion criteria

Study Design
  • RWE studies including:

    • Prospective observational studies

    • Retrospective studies

    • Registry analyses

    • Database analyses

    • Natural history studies and non-interventional studies

  • SLRs and meta-analyses (for cross-checking only)

  • Reviews

  • Editorials

  • Notes/comments/letters

  • Interventional studies

  • Studies with <20 patients in the whole population

  • Case reports/case series

Restrictions
  • English language

  • Studies in the United States, Western Europe, or Australia

  • Year limitation: 2010 to June 2020

  • Non-English language studies

  • Studies outside of United States, Western Europe, or Australia

* Studies with mixed populations of adults and children were included

Abbreviations: BOI, burden of illness; CKD, chronic kidney disease; ESRD, end-stage renal disease; IgAN, immunoglobulin A nephropathy; PICOS, Population, Intervention, Comparators, Outcomes, and Study Design; RWE, real-world evidence; SLR, systematic literature review.

b. BOI SLR
Category Inclusion Criteria Exclusion Criteria
Patient Population
  • Patients with IgAN regardless of comorbidities

  • Non-human

  • Patients with other diseases

Intervention
  • Any treatment or management

  • No treatment or management

  • Any non-IgAN treatment or management

Outcomes Measures
  • HRQoL outcomes

  • PROs

  • Utilities

  • Symptom burden

  • Costs (direct and indirect)/HCRU

  • BOI

  • Other QoL or economic burden

  • Studies that did not have ≥1 outcome in the inclusion criteria

Study Design
  • RWE studies including:

    • Prospective observational studies

    • Retrospective studies

    • Registry analyses

    • Database analyses

    • Natural history studies and non-interventional studies

  • SLRs and meta-analyses (for cross-checking only)

  • Reviews

  • Editorials

  • Notes/comments/letters

  • Interventional studies

  • Case reports/case series

Restrictions
  • English language

  • Year limitation: 2010 to June 2020

  • Non-English language studies

Abbreviations: BOI, burden of illness; HCRU, health-care resource utilization; HRQoL, health-related quality of life; IgAN, immunoglobulin A nephropathy; PRO, patient-reported outcome; QoL, quality of life; RWE, real-world evidence; SLR, systematic literature review.